Last reviewed · How we verify
Calcipotriene/betamethasone
Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while betamethasone is a corticosteroid that suppresses inflammation and immune response in the skin.
Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while betamethasone is a corticosteroid that suppresses inflammation and immune response in the skin. Used for Plaque psoriasis, Psoriatic dermatitis.
At a glance
| Generic name | Calcipotriene/betamethasone |
|---|---|
| Also known as | Taclonex |
| Sponsor | Derm Research, PLLC |
| Drug class | Vitamin D analog / Corticosteroid combination |
| Target | Vitamin D receptor (VDR) / Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Calcipotriene binds to vitamin D receptors on keratinocytes and immune cells, promoting normal differentiation and reducing excessive proliferation characteristic of psoriasis. Betamethasone acts as a glucocorticoid receptor agonist, rapidly suppressing inflammatory cytokines and immune cell infiltration. Together, they provide complementary anti-inflammatory and anti-proliferative effects on psoriatic plaques.
Approved indications
- Plaque psoriasis
- Psoriatic dermatitis
Common side effects
- Skin irritation or burning at application site
- Hypercalcemia (with excessive use)
- Local skin atrophy (corticosteroid-related)
- Pruritus
Key clinical trials
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (PHASE3)
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
- Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis (PHASE3)
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (PHASE2)
- The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcipotriene/betamethasone CI brief — competitive landscape report
- Calcipotriene/betamethasone updates RSS · CI watch RSS
- Derm Research, PLLC portfolio CI